Respiratory diseases have a significant impact from a medical and socioeconomic viewpoint. The World Health Organisation (WHO) consequently classifies pneumonia and chronic obstructive pulmonary disease (COPD) among the ten leading causes of death worldwide, accounting for 10 million deaths per year [source: European Lung White Book, 2003]. In Europe, the direct cost of the associated healthcare alone is at least 55 billion Euros annually, and when the indirect consequences are factored in (incapacity, life-years lost), the cost rises to close to 380 billion Euros. Despite this critical situation, the existing treatments are limited as they relieve some symptoms, but are seldom curative. These data underscore the urgent need to develop innovate research with the aim of achieving a better understanding of the pathophysiology of respiratory diseases and formulating more effective devices for targeted therapy.
Respiratory diseases have a major impact in medical and socio-economic terms. It is against this backdrop that the Center for Respiratory Diseases (CEPR) is aimed to develop innovative research that gives a better understanding of the pathophysiology of these diseases and improves inhalation therapy devices and aided by the numerous complementary resources of expertise existing within the 3 teams. In fact, CEPR’s staff includes immunologists, microbiologists, biochemists with an expertise in proteases and antiproteases, experts in aerosoltherapy, experts in murine and primate models of lung diseases as well as clinicians, all nationally and internationally recognised in their respective fields. Such diversity is an asset that allows for the development of research that is collaborative, translational as well as productive, and aimed at improving the treatments for two types of respiratory diseases.
|
|
|
|
Latest publications
-
Laura Gouzien, Didier Che, Sophie Cassaing, Olivier Lortholary, Valérie Letscher-Bru, et al.. Epidemiology and prognostic factors of mucormycosis in France (2012–2022): a cross-sectional study nested in a prospective surveillance programme. The Lancet Regional Health - Europe, 2024, 45, pp.101010. ⟨10.1016/j.lanepe.2024.101010⟩. ⟨hal-04688848⟩
-
Jean-Christophe Richard, François Beloncle, Gaëtan Béduneau, Satar Mortaza, Stephan Ehrmann, et al.. Pressure control plus spontaneous ventilation versus volume assist-control ventilation in acute respiratory distress syndrome. A randomised clinical trial. Intensive Care Medicine, 2024, 50, pp.1647-1656. ⟨10.1007/s00134-024-07612-3⟩. ⟨hal-04703842⟩
-
-
Nicolas Deye, Amelie Le Gouge, Bruno François, Camille Chenevier-Gobeaux, Thomas Daix, et al.. Can Biomarkers Correctly Predict Ventilator-associated Pneumonia in Patients Treated With Targeted Temperature Management After Cardiac Arrest? An Exploratory Study of the Multicenter Randomized Antibiotic (ANTHARTIC) Study. Critical Care Explorations, 2024, 6 (7), pp.e1104. ⟨10.1097/cce.0000000000001104⟩. ⟨hal-04674146⟩
-
-
-
Lucille Lamendour, Mäelle Gilotin, Nora Deluce-Kakwata Nkor, Zineb Lakhrif, Daniel Meley, et al.. Bispecific antibodies tethering innate receptors induce human tolerant-dendritic cells and regulatory T cells. Frontiers in Immunology, 2024, 15, pp.1369117. ⟨10.3389/fimmu.2024.1369117⟩. ⟨hal-04601179⟩
-
Ana Raquel Maia, Adeline Cezard, Delphine Fouquenet, Virginie Vasseur, Benoit Briard, et al.. Preventive nasal administration of flagellin restores antimicrobial effect of gentamicin and protects against a multidrug-resistant strain of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2024, 68 (5), pp.e01361-23. ⟨10.1128/aac.01361-23⟩. ⟨hal-04683300⟩
-
-
Cendrine Godet, Anne-Laure Brun, Francis Couturaud, François Laurent, Jean-Pierre Frat, et al.. CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma. Chest, 2024, 165 (6), pp.1307-1318. ⟨10.1016/j.chest.2024.02.026⟩. ⟨hal-04473459⟩